Literature DB >> 11219546

An overview of fungal infections.

G Garber1.   

Abstract

The incidence of fungal infections is increasing at an alarming rate, presenting an enormous challenge to healthcare professionals. This increase is directly related to the growing population of immunocompromised individuals, resulting from changes in medical practice such as the use of intensive chemotherapy and immunosuppressive drugs. HIV and other diseases which cause immunosuppression have also contributed to this problem. Superficial and subcutaneous fungal infections affect the skin, keratinous tissues and mucous membranes. Included in this class are some of the most frequently occurring skin diseases, affecting millions of people worldwide. Although rarely life threatening, they can have debilitating effects on a person's quality of life and may in some circumstances spread to other individuals or become invasive. Most superficial and subcutaneous fungal infections are easily diagnosed and readily amenable to treatment. Systemic fungal infections may be caused by either an opportunistic organism that infects an at-risk host, or may be associated with a more invasive organism that is endemic to a specific geographical area. Systemic infections can be life threatening and are associated with high morbidity and mortality. Because diagnosis is difficult and the causative agent is often confirmed only at autopsy, the exact incidence of systemic infections is difficult to determine. The most frequently encountered pathogens are Candida albicans and Aspergillus spp. but other fungi such as non-albicans Candida spp. are increasingly important.

Entities:  

Mesh:

Year:  2001        PMID: 11219546     DOI: 10.2165/00003495-200161001-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  87 in total

Review 1.  Endemic mycoses: a treatment update.

Authors:  O Lortholary; D W Denning; B Dupont
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

Review 2.  Disseminated histoplasmosis in the acquired immune deficiency syndrome: clinical findings, diagnosis and treatment, and review of the literature.

Authors:  L J Wheat; P A Connolly-Stringfield; R L Baker; M F Curfman; M E Eads; K S Israel; S A Norris; D H Webb; M L Zeckel
Journal:  Medicine (Baltimore)       Date:  1990-11       Impact factor: 1.889

3.  Detection and identification of fungal pathogens in blood by using molecular probes.

Authors:  H Einsele; H Hebart; G Roller; J Löffler; I Rothenhofer; C A Müller; R A Bowden; J van Burik; D Engelhard; L Kanz; U Schumacher
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

4.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

5.  Epidemiology of nosocomial fungal infections.

Authors:  S K Fridkin; W R Jarvis
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

7.  The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients.

Authors:  J H van Burik; W Leisenring; D Myerson; R C Hackman; H M Shulman; G E Sale; R A Bowden; G B McDonald
Journal:  Medicine (Baltimore)       Date:  1998-07       Impact factor: 1.889

8.  Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System.

Authors:  C Beck-Sagué; W R Jarvis
Journal:  J Infect Dis       Date:  1993-05       Impact factor: 5.226

9.  Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group.

Authors:  F Dromer; S Mathoulin; B Dupont; A Laporte
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

Review 10.  Options for the management of mucosal candidiasis in patients with AIDS and HIV infection.

Authors:  J A Vazquez
Journal:  Pharmacotherapy       Date:  1999-01       Impact factor: 4.705

View more
  49 in total

1.  Blue dye and red light, a dynamic combination for prophylaxis and treatment of cutaneous Candida albicans infections in mice.

Authors:  Tianhong Dai; Vida J Bil de Arce; George P Tegos; Michael R Hamblin
Journal:  Antimicrob Agents Chemother       Date:  2011-09-19       Impact factor: 5.191

2.  Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.

Authors:  Susanne Perkhofer; Helene Lugger; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

Authors:  Pasquale De Bellis
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  Repositioning the Old Fungicide Ciclopirox for New Medical Uses.

Authors:  Tao Shen; Shile Huang
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

Review 5.  Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.

Authors:  Petros Pechlivanoglou; Robin De Vries; Simon M G J Daenen; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2011-09       Impact factor: 4.981

6.  Aspergillus, Penicillium and Talaromyces isolated from house dust samples collected around the world.

Authors:  C M Visagie; Y Hirooka; J B Tanney; E Whitfield; K Mwange; M Meijer; A S Amend; K A Seifert; R A Samson
Journal:  Stud Mycol       Date:  2014-06       Impact factor: 16.097

7.  Virulence Factors and Antifungal Susceptibility in Candida Species Isolated from Dermatomycosis Patients.

Authors:  Victor Galvão Mello; Heloisa Escudeiro; Ana Carolina Villas Bôas Weckwerth; Maria Izilda Andrade; Ana Elisa Fusaro; Eloise Brasil de Moraes; Luciana da Silva Ruiz; Ida Maria Foschiani Dias Baptista
Journal:  Mycopathologia       Date:  2020-11-20       Impact factor: 2.574

8.  Role of phosphatidylinositol-3-kinase (PI3K), extracellular signal-regulated kinase (ERK) and nuclear transcription factor kappa beta (NF-k beta) on neutrophil phagocytic process of Candida albicans.

Authors:  E Giraldo; L Martin-Cordero; M D Hinchado; J J Garcia; E Ortega
Journal:  Mol Cell Biochem       Date:  2009-07-16       Impact factor: 3.396

9.  Fluconazole resistant opportunistic oro-pharyngeal Candida and non-Candida yeast-like isolates from HIV infected patients attending ARV clinics in Lagos, Nigeria.

Authors:  C A Enwuru; A Ogunledun; N Idika; N V Enwuru; F Ogbonna; M Aniedobe; A Adeiga
Journal:  Afr Health Sci       Date:  2008-09       Impact factor: 0.927

Review 10.  Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology.

Authors:  Jamie D Croxtall; Greg L Plosker
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.